title: Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
abstract: This 6-month, open, non-controlled, multicenter, dose-titration study evaluated the efficacy and safety of 28-day prolonged-release (PR) lanreotide in the treatment of carcinoid syndrome. Eligible patients had a carcinoid tumor with > or =3 stools/day and/or > or =1 moderate/severe flushing episodes/day. Six treatments of 28-day PR lanreotide were administered by deep subcutaneous injection. The dose for the first two injections was 90 mg. Subsequent doses could be titrated (60, 90, 120 mg) according to symptom response. Seventy-one patients were treated. Flushing decreased from a mean of 3.0 at baseline to 2.3 on day 1, and 2.0 on day 2, with a daily mean of 2.1 for the first week post-treatment (p < 0.05). Diarrhea decreased from a mean of 5.0 at baseline to 4.3 on day 1 (p < 0.05), and 4.5 on day 2, with a daily mean of 4.4 for the first week post-treatment (p < 0.001). Symptom frequency decreased further after the second and third injections, and reached a plateau after the fourth injection. By month 6, flushing and diarrhea had significantly decreased from baseline by a mean of 1.3 and 1.1 episodes/day, respectively (both p < or = 0.001); 65% of patients with flushing as the target symptom and 18% of diarrhea-target patients achieved > or =50% reduction from baseline. Median urinary 5-hydroxyindoleacetic acid and chromogranin A levels decreased by 24 and 38%, respectively. Treatment was well tolerated. 28-day PR lanreotide was effective in reducing the symptoms and biochemical markers associated with carcinoid syndrome.
authors.affiliation: Hôpital Beaujon, Clichy, France. philippe.ruszniewski@bjn.ap-hop-paris.fr
authors.forename: Philippe
authors.initials: P
authors.lastname: Ruszniewski
authors.forename: Sofia
authors.initials: S
authors.lastname: Ish-Shalom
authors.forename: Machteld
authors.initials: M
authors.lastname: Wymenga
authors.forename: Dermot
authors.initials: D
authors.lastname: O'Toole
authors.forename: Rudolf
authors.initials: R
authors.lastname: Arnold
authors.forename: Paola
authors.initials: P
authors.lastname: Tomassetti
authors.forename: Nigel
authors.initials: N
authors.lastname: Bax
authors.forename: Martyn
authors.initials: M
authors.lastname: Caplin
authors.forename: Barbro
authors.initials: B
authors.lastname: Eriksson
authors.forename: Benjamin
authors.initials: B
authors.lastname: Glaser
authors.forename: Michel
authors.initials: M
authors.lastname: Ducreux
authors.forename: Catherine
authors.initials: C
authors.lastname: Lombard-Bohas
authors.forename: Wouter W
authors.initials: WW
authors.lastname: de Herder
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Delle Fave
authors.forename: Nick
authors.initials: N
authors.lastname: Reed
authors.forename: Jean François
authors.initials: JF
authors.lastname: Seitz
authors.forename: Eric
authors.initials: E
authors.lastname: Van Cutsem
authors.forename: Ashley
authors.initials: A
authors.lastname: Grossman
authors.forename: Philippe
authors.initials: P
authors.lastname: Rougier
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Schmidt
authors.forename: Bertram
authors.initials: B
authors.lastname: Wiedenmann
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002864:Chromogranins / Q000097:blood; D003692:Delayed-Action Preparations / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation / Q000379:methods; D005260:Female; D005483:Flushing / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000097:blood / Q000627:therapeutic use*; D011788:Quality of Life; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D003969:Vipoma / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D002864:Chromogranins; D003692:Delayed-Action Preparations; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D006897:Hydroxyindoleacetic Acid